Matches in Wikidata for { <http://www.wikidata.org/entity/Q80365639> ?p ?o ?g. }
Showing items 1 to 33 of
33
with 100 items per page.
- Q80365639 description "clinical trial" @default.
- Q80365639 description "ensayu clínicu" @default.
- Q80365639 description "klinisch onderzoek" @default.
- Q80365639 description "клінічне випробування" @default.
- Q80365639 name "Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation" @default.
- Q80365639 name "Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation" @default.
- Q80365639 type Item @default.
- Q80365639 label "Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation" @default.
- Q80365639 label "Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation" @default.
- Q80365639 prefLabel "Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation" @default.
- Q80365639 prefLabel "Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation" @default.
- Q80365639 P1132 Q80365639-72109AE5-9849-4A8B-B175-16B1EAABB4B1 @default.
- Q80365639 P1476 Q80365639-AA089D35-B0A6-45EF-B42D-869D79DF8E3F @default.
- Q80365639 P2899 Q80365639-D58E10D1-55F3-4B8D-ABED-32A18734F2EE @default.
- Q80365639 P3098 Q80365639-1F5DBAFA-6B37-4339-AED8-5D5D3F8AB38A @default.
- Q80365639 P31 Q80365639-AE41FD42-4062-4E61-917B-3E46EB3BA256 @default.
- Q80365639 P4844 Q80365639-941F287D-410C-4E14-8E62-61E7966F61C3 @default.
- Q80365639 P580 Q80365639-CE6C8FA5-3E7E-417C-866A-9469A3F1F355 @default.
- Q80365639 P582 Q80365639-3C72447F-4399-4195-AEA4-9F2856CB7042 @default.
- Q80365639 P6099 Q80365639-045A869E-2D7E-43EA-B265-3DC32EC0AC88 @default.
- Q80365639 P8363 Q80365639-B690E8A6-8D0E-4E57-8C7F-FBDD45E99E1B @default.
- Q80365639 P859 Q80365639-10B03925-1653-4529-9EAB-C4E9F127EF70 @default.
- Q80365639 P1132 "+548" @default.
- Q80365639 P1476 "EPIK-B2: A Two Part, Phase III, Multicenter, Randomized (1:1), Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation" @default.
- Q80365639 P2899 "+18" @default.
- Q80365639 P3098 "NCT04208178" @default.
- Q80365639 P31 Q30612 @default.
- Q80365639 P4844 Q1998021 @default.
- Q80365639 P580 "2020-02-28T00:00:00Z" @default.
- Q80365639 P582 "2024-04-02T00:00:00Z" @default.
- Q80365639 P6099 Q42824827 @default.
- Q80365639 P8363 Q78089383 @default.
- Q80365639 P859 Q507154 @default.